enGene Therapeutics
ENGN · NASDAQ
$1.67+$0.09 (+5.70%)TodayMarket closed ·
Prev close $1.58
Who owns ENGN
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 65.2% of ENGN’s shares.
- Forbion Capital Partners14.4%
- BML Capital Management LLC10.0%
- Invus Public Equities Advisors, LLC9.3%
- Perceptive Advisors LLC7.2%
- Next 6 largest institutions24.4%
- All other shareholders34.8%
| Holder | Shares | % of shares |
|---|---|---|
| Forbion Capital Partners | 9.63M | 14.38% |
| BML Capital Management LLC | 6.67M | 9.96% |
| Invus Public Equities Advisors, LLC | 6.26M | 9.34% |
| Perceptive Advisors LLC | 4.82M | 7.20% |
| Lumira Ventures | 4.18M | 6.24% |
| Acorn Capital Advisors, LLC | 3.36M | 5.01% |
| Columbia Threadneedle Investments (US) | 2.68M | 3.99% |
| Nextech Invest, Ltd. | 2.32M | 3.47% |
| Adar1 Capital Management LLC | 2.10M | 3.14% |
| Vestal Point Capital, LP | 1.67M | 2.49% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 34.98K | 0.05% |
| Protea Fund - Sectoral Biotech Opportunities Fund | 21.70K | 0.03% |
| North Square Kennedy MicroCap Fund | 11.92K | 0.02% |
| JNL/DFA U.S. Small Cap Fund | 9.97K | 0.01% |
| Dimensional US Small Companies Fund | 3.80K | 0.01% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $10.05K (1 trade) of ENGN on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Grossman William | Buy | 5.10K | $10.05K |
| Heffernan Michael Thomas | Award | 31.00K | — |
| BRUNK GERALD A | Award | 31.00K | — |
| Astley-Sparke Philip | Award | 31.00K | — |
| Glickman Richard M | Award | 31.00K | — |
| HASTINGS PAUL J | Award | 31.00K | — |
| Zoth Lota S. | Award | 31.00K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 1.39M
- Days to cover
- 1.81
- % of shares outstanding
- 2.08%
- Average daily volume
- 770.26K
- Change since last report
- +16.2%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.